Not to provide any misleading information but just
Post# of 603
(Total Views: 90)
Posted On: 09/22/2025 8:23:38 AM
Not to provide any misleading information but just the facts should always be our objective. No insider information but the recent investor presentation mentioned an estimated market value of the UEEC stock as being $1-$2 which may or may not come to fruition. The projection of value was presented in the spreadsheet. Please do your due diligence mine tells me the value could be substantially more. Many medical projection buyouts are 4X sales? JMO!
$5-$10+ is a realistic value?
https://uhpcorp.com/united-health-products-to...mber-18th/
https://www.virtualinvestorconferences.com/wc...otcqb-ueec
https://on24static.akamaized.net/event/50/73/...484713.pdf
q Medical device technology company with patented, hemostatic agent.
o 280 million shares outstanding1
o $25M market cap
o Over 400 shareholders of record – mostly individual investors
o Approximately 150,000 ADTV over past three months
q Neutralized Organic Regenerated Cellulose (NORC) hemostatic woven gauze is superior hemostatic technology providing measurable advantages over
current standard of care.
o Human trial of CelluSTAT woven gauze indicated superiority to Surgicel® Original in time to hemostasis (97% CI).
o Gel and pressed gauze formats developed and tested in animal model.
o U.S. patent on carboxymethyl cellulose formula in effect until late 2029.
q Late-stage work underway with FDA to secure premarket approval for U.S. human surgical applications, with other markets to follow closely.
o Follow-up clinical work underway to respond to FDA request.
o Secure FDA Premarket Approval for woven gauze format followed by CE Mark and other authorizations.
o Will seek PMA Supplement approvals for complementary formats to build Class III product portfolio.
q Direct, capital-lite pathway to commercialization and U.S. market penetration.
o Seek well-capitalized distribution partner with complementary surgical products portfolio.
o Roll out and seek FDA PMA Supplement approvals for multiple surgical formats.
o Initiate regulatory approval applications in international markets.
o Maintain flexibility to sell the company at any time
$5-$10+ is a realistic value?
https://uhpcorp.com/united-health-products-to...mber-18th/
https://www.virtualinvestorconferences.com/wc...otcqb-ueec
https://on24static.akamaized.net/event/50/73/...484713.pdf
q Medical device technology company with patented, hemostatic agent.
o 280 million shares outstanding1
o $25M market cap
o Over 400 shareholders of record – mostly individual investors
o Approximately 150,000 ADTV over past three months
q Neutralized Organic Regenerated Cellulose (NORC) hemostatic woven gauze is superior hemostatic technology providing measurable advantages over
current standard of care.
o Human trial of CelluSTAT woven gauze indicated superiority to Surgicel® Original in time to hemostasis (97% CI).
o Gel and pressed gauze formats developed and tested in animal model.
o U.S. patent on carboxymethyl cellulose formula in effect until late 2029.
q Late-stage work underway with FDA to secure premarket approval for U.S. human surgical applications, with other markets to follow closely.
o Follow-up clinical work underway to respond to FDA request.
o Secure FDA Premarket Approval for woven gauze format followed by CE Mark and other authorizations.
o Will seek PMA Supplement approvals for complementary formats to build Class III product portfolio.
q Direct, capital-lite pathway to commercialization and U.S. market penetration.
o Seek well-capitalized distribution partner with complementary surgical products portfolio.
o Roll out and seek FDA PMA Supplement approvals for multiple surgical formats.
o Initiate regulatory approval applications in international markets.
o Maintain flexibility to sell the company at any time
(0)
(0)